BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06343779 (Deucrictibant in hereditary angioedema): BVCT ex-ante prediction vs. reported outcome

On 28 Jul 2025, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 3 Dec 2025 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient (moderately superior to KVD900).

Clinical Trial

NCTID
NCT06343779
Acronym
RAPIDe-3
Drug Name
Deucrictibant
Drug MoA
oral bradykinin B2 receptor antagonist
Drug Modality
small molecule
Drug Class
Best-In-Class
Therapeutic Area
Immune System Diseases
Indication
hereditary angioedema
Human Patients
134
Sponsor
Pharvaris
Phase
Phase 3

Prediction of , index 2044

Prospective Prediction
Prediction Index
2044
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit in PGI-C slightly-to-moderately superior to KVD900)
Technical Prediction
SUCCESS (statistically significant clinical benefit in PGI-C compared with placebo)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
128 days in advance
Readout Data Interpretation
deucrictibant met primary endpoint with median time to symptom relief 1.28 hours significantly faster than placebo (p<0.0001), which is moderately superior to 1.5-2.5 hours achieved by KVD900 in phase 2 trial (see add'l link below); no SAEs
Press Release
Additional Readout Data
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient (moderately superior to KVD900)
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults With Hereditary Angioedema
Phase
Phase 3
Status
Completed
Enrollment
134
Lead sponsor
Pharvaris Netherlands B.V.
Conditions
Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II; Hereditary Angioedema Types I and II; Hereditary Angioedema Attack; Hereditary Angioedema With C1 Esterase Inhibitor Deficiency; Hereditary Angioedema - Type 1; Hereditary Angioedema - Type 2; C1 Esterase Inhibitor [C1-INH] Deficiency; C1 Esterase Inhibitor Deficiency; C1 Esterase Inhibitor, Deficiency of; C1 Inhibitor Deficiency; Hereditary Angioedema - Type 3; Hereditary Angioedema Type III
Interventions
DRUG: Deucrictibant, Placebo
Design
Randomized · Crossover · Quadruple
Primary purpose
Treatment
Start
2024-02-26
Primary completion
2025-10-17
Completion
2025-10-17
Primary outcomes
  • Time to onset of symptom relief, defined as Patient Global Impression of Change (PGI-C) rating of at least "a little better" for 2 consecutive timepoints within 12 hours post-treatment. (Pre-treatment to 12 hours post-treatment.)

NCT06343779 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials